Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multicenter, Randomized, Double-Blind, Multiple-Dose, Placebo Controlled Clinical Trial of Two Doses of PP-01 for the Mitigation of Cannabis Withdrawal Symptoms

Trial Profile

A Phase 2, Multicenter, Randomized, Double-Blind, Multiple-Dose, Placebo Controlled Clinical Trial of Two Doses of PP-01 for the Mitigation of Cannabis Withdrawal Symptoms

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 02 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 19 Jun 2025 Results presented in the PleoPharma Media Release.
  • 19 Jun 2025 According to a PleoPharma, Inc. media release, the company presented a poster presentation on June 17, 2025 and an oral presentation on June 18, 2025 from this trial at the 2025 annual meeting of The College on Problems of Drug Dependence in New Orleans, LA.
  • 13 Feb 2025 According to a PleoPharma, Inc. media release, the company announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PP-01 for the mitigation of Cannabis Withdrawal Syndrome in patients with Cannabis Use Disorder.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top